Aurora Cannabis Inc (NASDAQ: ACB) rallied more than 25% this morning after President Trump endorsed cannabidiol (CBD) as potential breakthrough in senior healthcare.
In a social media post over the weekend, the US President said CBD could “revolutionise senior healthcare” and hinted at reclassifying marijuana at the federal level.
Aurora Cannabis stock has been in sharp uptrend over the past three months.
At the time of writing, the Edmonton-headquartered firm is up more than 50% versus the final week of June.
Trump news is majorly positive for Aurora Cannabis stock
Trump’s remarks on CBD and marijuana rescheduling are more than political noise – they signal a potential shift in federal cannabis policy.
Reclassification could eliminate Section 280E tax burdens, allowing cannabis companies to deduct standard business expenses and access US capital markets.
“Any support goes a long way for this beleaguered listed sector,” said Ben Laidler, equity strategist at Bradesco BBI.
Aurora, which has struggled with profitability and market saturation, could find new life through US partnerships, retail expansion, and institutional investment.
The news also boosts sentiment across the board, helping ACB stock regain investor attention after months of muted trading.
In short, Aurora Cannabis shares soared this morning as investors bet they will benefit if the US regulations ease.
ACB shares still remain unattractive to own in 2025
Trump’s positive stance is good news for the cannabis industry.
However, there are still a few idiosyncratic risks that warrant treading with caution on Aurora Cannabis stock.
For starters, the company’s fundamentals remain fragile. It has posted consecutive quarterly losses and continues to burn cash amid declining Canadian retail prices.
Its market cap, now hovering near $300 million, despite today’s surge, reflects investor skepticism about long-term viability.
Aurora Cannabis’ pivot to premium products and medical cannabis has yet to deliver consistent margin improvement.
Moreover, US regulatory reform, while promising, is still speculative.
“We are looking at reclassification. We will make a determination over the next few weeks,” Trump said in August.
Until concrete policy changes materialize, ACB shares’ valuation remains tethered to hope rather than earnings.
Investors should watch for balance sheet improvements and strategic US moves before betting on sustained upside.
How to play Aurora Cannabis following Trump’s CBD post
Aurora Cannabis’ stock price rally is emblematic of the sector’s sensitivity to political headlines.
Trump’s endorsement of CBD and potential rescheduling talks have reignited investor interest, but the path to regulatory reform is long and uncertain.
For ACB shares, today’s surge is a catalyst – not a cure.
The company must still prove it can navigate operational challenges, restore profitability, and capitalize on any US policy shifts.
Until then, Aurora Cannabis remains a speculative play, buoyed by momentum but grounded in fundamentals that demand caution.
Today’s surge, therefore, may be an opportunity to pull out of this cannabis stock instead of a signal to hold it for the longer term.
The post Why is Aurora Cannabis stock soaring today and will it last? appeared first on Invezz